Genome wide association studies (GWAS) have proven to be highly effective at defining causal relationships between single nucleotide polymorphisms (SNP) and clinical phenotypes in complex diseases. Establishing a mechanistic link between a non-coding SNP and the clinical outcome is a significant hurdle in translating associations into biological insight. We demonstrate an approach to assess the functional context of a diabetic nephropathy (DN) associated SNP located in the promoter region of the gene 
Introduction
While genome wide association studies are effective at projecting genetic variants to complex disease phenotype, establishing the corresponding mechanistic link remains difficult. This is especially true for SNPs in non-protein coding regions of the genome that may impact regulatory function in a manner that is only evident in a particular functional context (1) . One such context may be a biological process determined by genes whose transcription is synchronized by common regulatory elements within their promoters (2; 3). A SNP located in one of these regulatory elements may alter or disrupt this coordinated regulation, leading to a change in gene expression and subsequently phenotype. It may be possible to identify such a mechanism via a change to a transcription factor binding site (TFBS) by a candidate SNP; we demonstrate this strategy for a SNP affecting the diabetic nephropathy-associated bone morphogenetic protein (BMP) signaling pathway. The approach allows us to generate testable hypotheses from GWAS candidates falling in promoter regions, and has the potential to help understand the functional impact of genetic variants in diabetic nephropathy and other complex genetic diseases.
Diabetic nephropathy (DN) is a complex disease and the leading cause of end-stage renal disease in the U.S. (4) , and about 20-40% of all patients with either type 1 (T1D) or type 2 diabetes (T2D) develop DN (5) (6) (7) . DN has a significant heritability (8) , providing the rationale for performing GWAS to discover genetic loci implicated in DN (9) . Initial DN GWAS discovered candidate genetic loci for predisposition to DN for both T1D and T2D (8; 10) . However, these associations of a locus with DN do not explain how associated alleles affect the mechanism of disease. Unfortunately, this situation is typical of most GWAS of complex genetic disorders, while loci whose effects have been functionally confirmed are generally associated with Mendelian disorders. An example is the autosomal dominant disorder multiple osteochondromas, for which a SNP located in the EXT1 promoter, eliminates a TFBS and increases promoter activity (11) . For complex diseases, any large-scale analysis involving luciferase assays, electrophoretic mobility shift assays (EMSA) and enzyme-linked immunosorbent assays (ELISA) are simply not feasible for hundreds of diseases-associated SNPs. Data-driven approaches including the one outlined in this manuscript are necessary to prioritize the number of testable hypotheses for further experimental validation.
Establishing the functional context of a SNP is important in defining such hypotheses.
Our group has previously employed a functional context approach to identify proteins associated with the glomerular slit diaphragm in DN (12) . In that work, a regulatory module detected in the promoters of a few known slit diaphragm genes predicted other slit diaphragm molecules after a genome-wide promoter search. Here, our integrative approach combines regulatory SNP prediction, transcriptional promoter modeling and pathway analysis capable of decoding putative transcriptional pathomechanisms of DN (Fig. 1) . We focus on the candidate gene FERM domain containing 3 (FRMD3) identified by a GWAS of the Genetics of Kidneys in Diabetes (GoKinD) study collection (13) . In that study, the SNP rs1888747 showed the strongest risk association (P=4.7*10 -7 , OR=1.45) with DN within T1D subjects. Despite different study designs, this SNP also reached statistical significance level in a replication study of 1,305 participants of the DCCT/EDIC study, as well as in a subcohort of Japanese subjects with T2D (14) . This polymorphism remained significantly associated with DN in a random-effects metaanalysis of genetic variants reproducibly associated with DN (15) . Additionally, we have recently shown that rs1888747 is significantly associated with DN among 66 large T2D
families from the Joslin T2D family collection (Pezzolesi et al., in preparation) . The SNP rs1888747 is located on chromosome 9q in the extended promoter region of FRMD3.
FRMD3 has not previously been implicated in the pathogenesis of DN, T1D or T2D.
Here we describe both our in-silico approach, and its use to derive the hypothesis that a DN risk allele brings FRMD3 under the control of a proposed transcriptional regulatory module and inhibits renal expression of FRMD3. Not only does the approach detect a transcriptional regulatory pattern affected by the candidate SNP, it also connects known DN-associated pathways to the GWAS-derived candidate gene, providing the testable model system for further insight into the pathophysiology of DN.
Research Design and Methods

Strategy
We hypothesized that the SNP rs1888747, reported to be associated with DN by Pezzolesi et al. (13) and located in the proximity of FRMD3, is a regulatory SNP that alters the transcription factor binding capabilities of the FRMD3 proximal promoter region. We assumed that the binding site putatively affected by the SNP is part of a molecular TFBS framework involved in this transcriptional change, which should also be conserved in promoters of functionally connected (i.e. co-varying) transcripts. Finding those transcripts might enable us to detect the framework by including the polymorphism in the FRMD3 promoter, and thus place the SNP into a DN-relevant functional context.
We used comparative promoter analysis to determine common regulatory elements of FRMD3 and its co-expressed transcripts. Promoters of functionally linked transcripts are likely to contain conserved (non-random associated) TFBS frameworks. SNP-related TFBS alterations have the potential to integrate genomic features with transcriptional regulatory functions. A detailed overview of our study and strategy can be found in Fig.   1 .
Human Renal Biopsies
Renal biopsy samples were procured from 22 participants in a clinical trial, whose extended follow-up provides an opportunity to examine the etiology of DN in T2D as well as the effect of treatment with losartan on the onset and progression of diabetic kidney disease (Study Title: Renoprotection in Early Diabetic Nephropathy in Pima Indians, ClinicalTrials.gov Identifier: NCT00340678). Renal Biopsy specimens were processed and analyzed as described previously (12; 16; 17) . Subjects' aggregate clinical and histological characteristics are summarized in Suppl. (19) , the albumin creatinine ratio (ACR) and the fractional mesangial area were compared between the two clusters.
The delta in ACR/year and the delta in iGFR (mL/min)/year were calculated by subtracting the corresponding value from the time of enrollment into the study from the latest available value divided by the number of years of follow up. Fractional mesangial area was determined as described previously (20) . Statistical analysis comparing the two major cluster branches was done using GraphPad Prism 5 with a two-tailed t-test (MannWhitney U, 95% confidence interval). A P<0.05 was considered statistically significant.
Computational Promoter Analysis and Evaluation
Promoter regions for the eight FRMD3 co-expressed BMP pathway members were We searched for a common module among promoter sequences of a subset of the 8 FRMD3 co-expressed BMP pathway members and the SNP-altered sequence of the FRMD3 promoter (Genomatix® FrameWorker). Variance, and distance between the individual promoter elements were altered until a module with more than two elements was discovered. We required more than two elements to be identified in our search since more complex modules have been shown to be associated with more specific biological function (22) . In addition, the promoter module was required to occur in at least 2 of the 8 FRMD3 co-expressed BMP pathway members as well as in the FRMD3 promoter sequence at the position of rs1888747.
We evaluated the significance of the promoter module by searching a genome wide human promoter database for additional genes whose promoters would also contain potential binding capabilities for the defined framework identified in the previous step (Genomatix® ModelInspector). To achieve comparable preconditions, this search was conducted after adjusting the promoter sequence of all genes in the promoter database complimentary strands, were annealed and end-labeled with 32-P-dCTP (24) . Nuclear protein extracts were incubated in buffer with poly dIdC or poly dAdT and 10,000 cpm of end-labeled oligonucleotide as described previously (24) . For competition experiments, unlabeled DNA was added to the binding reactions at a 100-fold excess of the radiolabelled oligonucleotide. The DNA-protein complexes were resolved on 6% nondenaturing polyacrylamide gels in Tris-Borate-EDTA buffer at 120V for 2.5 hours. Gels were dried and exposed to XOMAT film (Eastman Kodak) overnight. The intensity of the DNA-protein complex was measured using the software ImageJ 1.44p from the NIH (http://imagej.nih.gov/ij/). A paired t-test (GraphPad Prism 5) was used to assess the significance of the mean intensity in the SNP sequences compared to the WT-sequence.
Results
Defining clinical and functional association of FRMD3
To assess the functional relationship between FRMD3 and DN, we related steady state mRNA levels with the available clinical outcome parameters. We found and the disease.
We identified 581 FRMD3 co-expressed transcripts (|r|≥0.65, FDR≤0.02; for top 10 transcripts with the highest |r|-value, see Suppl. Table 1 ). The majority (518) of the 581 FRMD3 co-expressed transcripts were concordantly regulated with FRMD3, as were the 
Pathway analysis of FRMD3 co-expressed transcripts
We determined the functional context of FRMD3 and its 581 co-expressed transcripts by mapping them to known canonical pathways. Among them, the BMP signaling pathway was found to be the pathway with the strongest enrichment with eight BMP pathway members co-expressed with FRMD3 (BMPR2, CREB1, KRAS, MAP3K7, PRKAR1B, PRKAR2B, SMAD5, and XIAP) (Fig. 3) . This finding is consistent with previous publications attributing DN-protective properties to the BMP pathway (for review, see (26; 27) ) and indicates that the biological context defined for FRMD3 and its coexpressed transcripts might indeed be relevant for DN.
Defining putative SNP function
In-silico comparison of sequence variants with and without the risk allele identified a potential homeodomain factor (HOMF) TFBS covering the SNP position. This TFBS was not detected in the presence of the non-risk allele in the FRMD3 promoter (Fig. 1, step 2 ). This strategy presented in our study is applicable whenever a transcriptional change of the GWAS gene is observed and co-regulated transcriptional networks can be identified.
However, although this implies finding a group of co-expressed genes, the pathway association might not always be as clear-cut as in our case, which might result in testing multiple associated pathways with the strategy presented above. A direct hit of the SNP in a TFBS is an advantage but proximity to a potential TFBS framework most likely would suffice to alter TFBS function. In case no such framework can be found with any associated pathway, alternative bioinformatics methods for the selection of genes of a similar functional context can be tested: including protein-protein interaction networks (34) , phylogenetic conservation (12) or epigenetic/epigenomic approaches (35) . With the increasing availability of genetic mapping of expression quantitative trait loci (eQTL) studies in DN cohorts, eQTLs will be linked directly to the physical location of transcripts differentially expressed in DN and thereby support promoter modeling approaches as described by our example (36; 37).
The study presented here started from a worst case scenario, as a testable hypothesis had to be developed for the role of a non-coding SNP in a gene without known function in DN. We followed a sequential strategy integrating multiple lines of genetic and genomic evidence for hypothesis generation (see Fig. 1 for overview) . First, the candidate SNP rs1888747 in the proximal promoter region of FRMD3 prompted us to search for the functional context of the TFBS framework covering the candidate SNP. Pathway analysis of co-expressed transcripts revealed a significant enrichment for the BMP pathway (38) .
BMPs are part of the transforming growth factor β superfamily (39) and have a wellestablished role in kidney development, cell growth, cell differentiation, chemotaxis and apoptosis of various cell types (40) . An imbalance of BMP-7 agonists like Kielin/chordinlike protein and BMP-7 antagonists like Gremlin has been described in DN (27) .
Decreased expression of BMP-7 and its agonists has been associated with increased profibrotic activity in animal models of DN (41) Insulin receptor signaling pathway, results from these functional assays can be interpreted with regard to all pathways shown to be enriched among FRMD3-correlated transcripts.
Conclusion
Our work provides a paradigm of how functional genomics based hypothesis generation can be implemented by a stepwise integration of regulatory SNP prediction, transcriptional promoter modeling and pathway analysis. Our model approach provides a novel strategy to extend insight into the mechanisms of genomic variation and transcriptional regulation to regulatory networks informing subsequent experimental design. The general approach can be applied for different questions in the field of GWAS and transcriptomic data integration. The method is also suitable for the analysis of experimentally derived TFBS data sets, such as ChIP-Seq data or panels of in vivo protein bound DNA elements, generated by genomic footprinting (45) . Furthermore, information from chromatin histone modifications, potentially regulatory sequences, or phylogenetic footprinting studies can be linked to regulatory networks. In the context of DN our work presents a novel starting point for hypothesis generation in molecular medicine in DN.
Author Contributions
The project was conceived and the experiments were designed by S.M, V.N, and M.K. showed that the mean intensity was significantly higher in the SNP sequences compared to the WT-sequence (P=0.04). support and reflect distinct clinical groups (see Fig. 2D ). Fig. 2 C: FRMD3 and co-regulated BMP pathway members are repressed in cluster 1. FRMD3 and BMPR2, CREB1, KRAS, MAP3K7, PRKAR2B, SMAD5, XIAP (7 of 8 BMP pathway members) are significantly (**P<0.008) down-regulated in cluster 1 compared to cluster 2 (Mann-Whitney U, two tailed, 95% confidence interval). Expression data are displayed as mean±standard deviation. Glomerular FRMD3 expression cluster 1: 8.29±0.54, cluster 2: 9.67±0.41. amounts of protein used a distinct binding signal can be detected in the SNP-sequence but to a lesser amount in the WT-sequence as displayed in the Intensity Blot B). Intensity of the DNA-protein complex in lane 2 was set to 1.0. A paired t-test showed that the mean intensity was significantly higher in the SNP sequences compared to the WT-sequence (P=0.04).
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